Not yet recruiting
Efficacy And Safety of Olatorepatide in Adults With Overweight or Obesity Without Diabetes
NCT07896265· Phase 3· Regeneron Pharmaceuticals· Source
Not yet recruiting
A pivotal clinical study to investigate the safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis due to Metabolic dysfunction-associated steatohepatitis (MASH)
2026-525755-82-00· Phase 3· Glaxosmithkline Research & Development Limited· Source
Not yet recruiting
A study to investigate safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis (stage F4 fibrosis) due to MASH (NEBULA-2)
2026-525757-37-00· Phase 3· Glaxosmithkline Research & Development Limited· Source
Recruiting
Study to Evaluate the Safety and Preliminary Efficacy of CD19 CAR-T Cell Therapy (TranspoCART19) in Patients With Refractory Lupus Nephritis
NCT07799116· Phase 1/2· Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz· Source
Recruiting
A Phase 3 Study Comparing Ramantamig plus Daratumumab Versus DVRd or DRd in Participants With NDMM for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
2026-526654-14-01· Phase 3· Janssen Cilag International· Source
Recruiting
Influence of Doxycycline Use as Prophylaxis for Sexually Transmitted Infections on Bacterial Resistance and Gut Microbiota: MiDoxyR-PEP Study
2025-525150-19-01· Phase 4· Instituto De Investigacion Marques De Valdecilla· Source
Recruiting
Phase 2 Randomized, Double-blind, Placebo-controlled Study of Prophylactic
Tocilizumab to Prevent Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma
2025-524793-42-00· Phase 2· Janssen Cilag International· Source
Recruiting
A trial to learn how safe elecoglipron is and how well it works in adults living with obesity or excess body weight with or without type 2 diabetes
2025-524688-19-00· Phase 3· AstraZeneca AB· Source
Not yet recruiting
Treatment for Ph-negative ALL for Adults up to 65 Years
NCT07443592· PETHEMA Foundation· Source
Contact: Nora Suárez, Dr (principal investigator)
Recruiting
Effect of Intravenous Iron on Quality of Life in Older Patients With Acute Coronary Syndrome
NCT07476859· Phase 4· Fundación para la Investigación del Hospital Clínico de Valencia· Source
Contact: Maria Thiscal López Lluva, Doctor
Recruiting
Effect of intravenous iron on quality of life in older adults with acute coronary syndrome: a phase IV clinical study
2025-522421-36-00· Phase 4· Instituto De Investigacion Sanitaria Fundacion Para La Investigacion Del Hospital Clinico De Valencia-INCLIVA· Source
Recruiting
LONG NAGOMI™ PMCF STUDY
NCT07399002· Fundación EPIC· Source
Contact: TAMARA GARCIA CAMARERO, MD, PhD
Recruiting
Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management
NCT07371585· Phase 2· SOLTI Breast Cancer Research Group· Source
Recruiting
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
NCT07284758· Phase 2· C4 Therapeutics, Inc.· Source
Recruiting
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
NCT07095452· Phase 2/3· AbbVie· Source
Recruiting
A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Understanding and Management of Coronary Calcium (The Optimal Trial)
NCT07286578· Fundación EPIC· Source
Contact: CAROLINA FOCELLA
Recruiting
Comparison of a Contemporary Sirolimus-eluting Stent (ihtDEStiny®) With Another Everolimus-eluting Stent (Xience™), Both With Permanent Polymers, in Patients With Acute Coronary Syndrome and de Novo Coronary Artery Lesions
NCT07190690· Fundación EPIC· Source
Contact: Armando Pérez de Prado, MD, PhD
Recruiting
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
NCT07221188· Phase 3· GlaxoSmithKline· Source
Recruiting
Real-life Registry in Patients With Coronary Artery Disease Treated With the SELUTION Sirolimus-eluting Balloon. Selution Iberia Registry
NCT07256249· Fundación EPIC· Source
Contact: ORIOL RODRIGUEZ LEOR, MD, PhD
Recruiting
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
NCT07085767· Phase 3· Olema Pharmaceuticals, Inc.· Source
Recruiting
Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome
NCT07168434· Phase 3· Biocodex· Source
Active, not recruiting
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)
2024-516652-18-00· Phase 3· Amgen Inc.· Source
Active, not recruiting
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
NCT07037433· Phase 3· Amgen· Source
Recruiting
Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis
NCT06315010· Phase 2· MedSIR· Source
Recruiting
PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML
NCT06409936· Phase 2· Gruppo Italiano Malattie EMatologiche dell'Adulto· Source
Recruiting
Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.
NCT06431633· Phase 3· Fundación GECP· Source
Recruiting
ANALYSIS OF EFFECTIVENESS OF NEOADJUVANT CHEMOTHERAPY IN THE TREATMENT OF LOCALLY ADVANCED COLON CANCER.
2024-519825-39-00· Phase 2· Clinica Universidad De Navarra· Source
Recruiting
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
NCT06712316· Phase 2/3· BioNTech SE· Source
Recruiting
Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC
NCT06078384· Phase 2· UNICANCER· Source
Recruiting
DEBSCAN-IVL. Drug Eluting Balloon or Drug Eluting Stent to Treat CAlcified Nodules After IntraVascular Lithotripsy.
NCT06657833· Fundación EPIC· Source
Contact: FUNDACION EPIC
Recruiting
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
NCT06382948· Phase 3· MedSIR· Source
Recruiting
DRUG RELEASING BALL vs. PHARMACOACTIVE STENT IN LARGE VESSELS: MORPHOLOGICAL ANALYSIS AND FUNCTION VASOMOTOR (DEBORA STUDY) IN LARGE VESSELS: MORPHOLOGICAL ANALYSIS AND FUNCTION VASOMOTOR (DEBORA STUDY)
NCT06448637· Fundación EPIC· Source
Contact: IÑIGO LOZANO MARTINEZ-LUENGAS, MD, PhD
Recruiting
Safety and Effectiveness of Short-Term Single AntiPlatelet Therapy After Left Atrial Appendage Closure With the LAmbre Device in Patients With Nonvalvular Atrial Fibrillation: A Multinational Real-world Registry
NCT06620757· Fundación EPIC· Source
Contact: BEATRIZ VAQUERIZO, MD, PhD
Active, not recruiting
PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer
NCT06172127· Phase 2· MedSIR· Source
Active, not recruiting
Comparison Between Optical Coherence Tomography and Intravascular Ultrasound for Intermediate Left Main Coronary Artery Lesions
NCT06272643· Fundación EPIC· Source
Active, not recruiting
PREVAIL Paclitaxel-coated Balloon in Small Coronary Disease and High-bleeding Risk Patients
NCT06321757· Fundación EPIC· Source
Recruiting
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT06016738· Phase 3· Olema Pharmaceuticals, Inc.· Source
Active, not recruiting
An open label, multicenter, phase II study of Elranatamab as single agent for the treatment of relapsed or refractory myeloma in patients previously exposed to three-drug classes
2023-504273-21-00· Phase 2· Pethema Fundacion· Source
Active, not recruiting
Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet Therapy
NCT05952206· Phase 3· iVascular S.L.U.· Source
Recruiting
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT05730036· Phase 3· Regeneron Pharmaceuticals· Source
Recruiting
The ReTAVI Prospective Observational Registry
NCT05601453· Institut für Pharmakologie und Präventive Medizin· Source
Contact: María López Benito, Dr.
Recruiting
Coroflex® ISAR NEO PMCF Study
NCT05698732· Fundación EPIC· Source
Contact: koldobika García San Román, MD, PhD
Recruiting
SUPRAFLEX CRUZ PMCF Study ( rEpic05 )
NCT05617599· Fundación EPIC· Source
Contact: Bruno Garcia, MD, PhD
Active, not recruiting
Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System in Complex PCI Patients
NCT05705973· Terumo Europe N.V.· Source
Active, not recruiting
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05572515· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
Sequent Extended Study
NCT05788432· Fundación EPIC· Source
Active, not recruiting
Treatment of Functionally Non-significant Vulnerable Plaques in Patients With Multivessel ST-elevation Myocardial Infarction The VULNERABLE Trial
NCT05599061· Fundación EPIC· Source
Recruiting
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
NCT05712200· Phase 3· Anthos Therapeutics, Inc.· Source
Active, not recruiting
Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.
NCT05527340· Phase 2· PETHEMA Foundation· Source
Showing 50 of 68.